1-5 of 5
Heidi McIntyre
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

Clinical Trials & Observations
Hervé Dombret, John F. Seymour, Aleksandra Butrym, Agnieszka Wierzbowska, Dominik Selleslag, Jun Ho Jang, Rajat Kumar, James Cavenagh, Andre C. Schuh, Anna Candoni, Christian Récher, Irwindeep Sandhu, Teresa Bernal del Castillo, Haifa Kathrin Al-Ali, Giovanni Martinelli, Jose Falantes, Richard Noppeney, Richard M. Stone, Mark D. Minden, Heidi McIntyre, Steve Songer, Lela M. Lucy, C. L. Beach, Hartmut Döhner
Journal: Blood
Blood (2015) 126 (3): 291–299.
https://doi.org/10.1182/blood-2015-01-621664
Published: 2015
Includes: Supplemental data
Journal Articles

Overall Survival in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with >30% Bone Marrow Blasts Treated with Azacitidine By Cytogenetic Risk Status: Results of the AZA-AML-001 Study

Hartmut Döhner, MD, John F Seymour, MBBS, FRACP, PhD, Aleksandra Butrym, MD, Agnieszka Wierzbowska, MD PhD, Dominik Selleslag, MD, Jun Ho Jang, MD, James D Cavenagh, MD, Rajat Kumar, FRCPC, Andre C Schuh, MD FRCPC, Anna Candoni, MD, Christian Récher, MDPhD, Irwindeep Sandhu, MD FRCPC, Teresa Bernal del Castillo, MD, Haifa Kathrin Al-Ali, MD, Giovanni Martinelli, MD, Jose Falantes, MD, Richard M. Stone, MD, Mark D. Minden, MD PhD, Heidi McIntyre, BS, Stephen Songer, PharmD, Lela M. Lucy, MS, CL Beach, PharmD, Hervé Dombret, MD
Journal: Blood
Blood (2014) 124 (21): 621.
https://doi.org/10.1182/blood.V124.21.621.621
Published: 2014
Journal Articles

Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (>30% Bone Marrow Blasts) with Morphologic Dysplastic Changes: A Subgroup Analysis of the AZA-AML-001 Trial

John F Seymour, MBBS, FRACP, PhD, Hartmut Döhner, MD, Aleksandra Butrym, MD, Agnieszka Wierzbowska, MD PhD, Dominik Selleslag, MD, Jun Ho Jang, MD, James D Cavenagh, MD, Rajat Kumar, MD, Andre C. Schuh, MD FRCPC, Anna Candoni, MD, Christian Récher, MDPhD, Irwindeep Sandhu, MD FRCPC, Teresa Bernal del Castillo, MD, Haifa Kathrin Al-Ali, MD, Giovanni Martinelli, MD, Jose Falantes, MD, Richard M Stone, Mark D. Minden, MD PhD, Heidi McIntyre, BS, Stephen Songer, PharmD, Lela M. Lucy, MS, CL Beach, PharmD, Hervé Dombret, MD
Journal: Blood
Blood (2014) 124 (21): 10.
https://doi.org/10.1182/blood.V124.21.10.10
Published: 2014
Journal Articles

Results of the Initial Treatment Phase of a Study of Three Alternative Dosing Schedules of Azacitidine (Vidaza®) in Patients with Myelodysplastic Syndromes (MDS).

Roger M. Lyons, MD, Thomas Cosgriff, MD, Sanjiv Modi, MD, Heidi McIntyre, Indra Fernando, Jay Backstrom, MD, C.L. Beach, PharmD
Journal: Blood
Blood (2007) 110 (11): 819.
https://doi.org/10.1182/blood.V110.11.819.819
Published: 2007
Journal Articles

Hematologic Improvement, Transfusion Independence, and Safety Assessed Using Three Alternative Dosing Schedules of Azacitidine in Patients with Myelodysplastic Syndromes.

Roger M. Lyons, MD, Thomas Cosgriff, MD, Sanjiv Modi, MD, Heidi McIntyre, BA, C.L. Beach, PharmD, Jay T. Backstrom, MD, MPH
Journal: Blood
Blood (2006) 108 (11): 2662.
https://doi.org/10.1182/blood.V108.11.2662.2662
Published: 2006